Predictive role of MGMT and IDH status in the efficacy of bevacizumab for high-grade glioma: a retrospective study

BackgroundThe objective of this study is to investigate the predictive role of O6-methylguanine-DNA methyltransferase (MGMT) and isocitrate dehydrogenase (IDH) status on the efficacy of bevacizumab (BEV) in high-grade glioma (HGG), while excluding the interference of chemotherapy agents.MethodsA ret...

Full description

Saved in:
Bibliographic Details
Main Authors: Bai Xuexue, Yan Chengrui, Wenbin Ma, Feng Ming, Wu Chao
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1634892/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849225199480733696
author Bai Xuexue
Yan Chengrui
Wenbin Ma
Feng Ming
Wu Chao
author_facet Bai Xuexue
Yan Chengrui
Wenbin Ma
Feng Ming
Wu Chao
author_sort Bai Xuexue
collection DOAJ
description BackgroundThe objective of this study is to investigate the predictive role of O6-methylguanine-DNA methyltransferase (MGMT) and isocitrate dehydrogenase (IDH) status on the efficacy of bevacizumab (BEV) in high-grade glioma (HGG), while excluding the interference of chemotherapy agents.MethodsA retrospective, single-center analysis was conducted on 103 patients with HGG who received BEV treatment. The enrolled patients were grouped based on their different biomarker statuses. Depending on whether the numerical variables of the patients satisfied the normal distribution, t-test or rank-sum test was employed. Chi-square test was used for the comparison of categorical variables. Univariate and multivariate Cox regression analyses were performed to identify prognostic factors affecting progression-free survival (PFS) and overall survival (OS).ResultsMultivariate COX regression analysis revealed that pathological grade, extent of resection, MGMT status, and IDH status were independent factors influencing PFS and OS in patients with HGG. The PFS, OS, and therapeutic response were superior in the MGMT methylated group compared to the unmethylated group. Similarly, patients with IDH mutations exhibited better PFS, OS, and therapeutic response than those with IDH wild-type.ConclusionsAfter controlling for potential confounding effects of chemotherapeutic agents, HGG patients with concurrent MGMT methylation and IDH mutations are likely to derive greater benefit from BEV treatment.
format Article
id doaj-art-ab9dfea08d8c4a59b771863bfa4c8a8c
institution Kabale University
issn 2234-943X
language English
publishDate 2025-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj-art-ab9dfea08d8c4a59b771863bfa4c8a8c2025-08-25T05:26:21ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-08-011510.3389/fonc.2025.16348921634892Predictive role of MGMT and IDH status in the efficacy of bevacizumab for high-grade glioma: a retrospective studyBai Xuexue0Yan Chengrui1Wenbin Ma2Feng Ming3Wu Chao4Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaDepartment of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaDepartment of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaDepartment of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaDepartment of Neurosurgery, Tengzhou Central People’s Hospital, Tengzhou, Shandong, ChinaBackgroundThe objective of this study is to investigate the predictive role of O6-methylguanine-DNA methyltransferase (MGMT) and isocitrate dehydrogenase (IDH) status on the efficacy of bevacizumab (BEV) in high-grade glioma (HGG), while excluding the interference of chemotherapy agents.MethodsA retrospective, single-center analysis was conducted on 103 patients with HGG who received BEV treatment. The enrolled patients were grouped based on their different biomarker statuses. Depending on whether the numerical variables of the patients satisfied the normal distribution, t-test or rank-sum test was employed. Chi-square test was used for the comparison of categorical variables. Univariate and multivariate Cox regression analyses were performed to identify prognostic factors affecting progression-free survival (PFS) and overall survival (OS).ResultsMultivariate COX regression analysis revealed that pathological grade, extent of resection, MGMT status, and IDH status were independent factors influencing PFS and OS in patients with HGG. The PFS, OS, and therapeutic response were superior in the MGMT methylated group compared to the unmethylated group. Similarly, patients with IDH mutations exhibited better PFS, OS, and therapeutic response than those with IDH wild-type.ConclusionsAfter controlling for potential confounding effects of chemotherapeutic agents, HGG patients with concurrent MGMT methylation and IDH mutations are likely to derive greater benefit from BEV treatment.https://www.frontiersin.org/articles/10.3389/fonc.2025.1634892/fullbevacizumabhigh-grade gliomaMGMTIDHpredictor
spellingShingle Bai Xuexue
Yan Chengrui
Wenbin Ma
Feng Ming
Wu Chao
Predictive role of MGMT and IDH status in the efficacy of bevacizumab for high-grade glioma: a retrospective study
Frontiers in Oncology
bevacizumab
high-grade glioma
MGMT
IDH
predictor
title Predictive role of MGMT and IDH status in the efficacy of bevacizumab for high-grade glioma: a retrospective study
title_full Predictive role of MGMT and IDH status in the efficacy of bevacizumab for high-grade glioma: a retrospective study
title_fullStr Predictive role of MGMT and IDH status in the efficacy of bevacizumab for high-grade glioma: a retrospective study
title_full_unstemmed Predictive role of MGMT and IDH status in the efficacy of bevacizumab for high-grade glioma: a retrospective study
title_short Predictive role of MGMT and IDH status in the efficacy of bevacizumab for high-grade glioma: a retrospective study
title_sort predictive role of mgmt and idh status in the efficacy of bevacizumab for high grade glioma a retrospective study
topic bevacizumab
high-grade glioma
MGMT
IDH
predictor
url https://www.frontiersin.org/articles/10.3389/fonc.2025.1634892/full
work_keys_str_mv AT baixuexue predictiveroleofmgmtandidhstatusintheefficacyofbevacizumabforhighgradegliomaaretrospectivestudy
AT yanchengrui predictiveroleofmgmtandidhstatusintheefficacyofbevacizumabforhighgradegliomaaretrospectivestudy
AT wenbinma predictiveroleofmgmtandidhstatusintheefficacyofbevacizumabforhighgradegliomaaretrospectivestudy
AT fengming predictiveroleofmgmtandidhstatusintheefficacyofbevacizumabforhighgradegliomaaretrospectivestudy
AT wuchao predictiveroleofmgmtandidhstatusintheefficacyofbevacizumabforhighgradegliomaaretrospectivestudy